AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02852668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: This experimental groups underwent an intervention period of power training
Study NCT02852668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: This experimental groups underwent an intervention period of strength training
Study NCT03176667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
Study NCT03176667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal block
Description: The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
Study NCT04057911 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NIBS
Description: The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
Study NCT02013661 — intervention group
Intervention type: PROCEDURE
Intervention: Periodontal resective surgery
Description: surgical periodontal debridement is performed after periodontal phase I
Study NCT01758107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdraw cyclosporine
Study NCT02382237 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/TDM
Description: Evaluation of nutrition absorption by TEP/TDM
Study NCT04867876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
Study NCT06623500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine excess
Description: Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L
Study NCT06623500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine suitable
Description: Iodine suitable areas：water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
Study NCT02235051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo Curves exercise program
Study NCT02235051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02235051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02235051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02279745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralinepag
Description: Active
Study NCT04561102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test for detection of SARS-CoV-2
Description: The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
Study NCT01575275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given PO
Study NCT01575275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT02413242 — intervention group
Intervention type: OTHER
Intervention: Various observed exposure(s) of interest
Description: A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
Study NCT03588078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
Study NCT03588078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
Study NCT04112160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IM injection of either normal saline or Ketorolac
Study NCT04112160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline
Study NCT01503398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg
Study NCT01503398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg
Study NCT00570544 — intervention group
Intervention type: DRUG
Intervention: tiotropium
Description: 18ug capsule daily for 30 days
Study NCT00108342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum - 2 mg and 4 mg
Study NCT00108342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenges - 2 mg and 4 mg
Study NCT00108342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing
Description: can yield 4 mg from 10 mg device - infrequent and frequent puffing
Study NCT00108342 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Computer learning
Study NCT01451944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: home asthma case management and education
Study NCT02052596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
Study NCT02052596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
Study NCT02052596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: 1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
Study NCT02052596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: 1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
Study NCT02362776 — intervention group
Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood
Study NCT00453310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT00783471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, Docetaxel
Description: Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
Study NCT00783471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Erlotinib
Description: Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
Study NCT02599090 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
Study NCT02599090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Study NCT02183350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - single rising dose
Study NCT02183350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04059393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete web-based legacy intervention
Study NCT01448382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam® capsule with Given PillCam® Platform
Description: capsule endoscopy
Study NCT01177137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional sound generator (SG)
Description: Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
Study NCT01177137 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo sound generator (placebo SG)
Description: Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
Study NCT01177137 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care (SC)
Description: The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
Study NCT01177137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directive Counseling (DC)
Description: Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
Study NCT01177137 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Directive Counseling (DC)
Description: Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
Study NCT04097691 — intervention group
Intervention type: DRUG
Intervention: GLUCOSE 10%
Description: subcutaneous glucose 0.5 ml per site around subcutaneous nerves
Study NCT04047225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THE ANALGESIA NOCICEPTIVE INDEX (ANI)
Description: Utilisation of the ANI during the operation
Study NCT01816100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specifically design 6 month resistance training program
Description: Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
Study NCT01816100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 months weight resistance and balance program
Description: 3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
Study NCT04059393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT04059393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04059393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04059393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04059393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02049060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: •- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
Study NCT01093222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01093222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT04051190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLED group
Description: 10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
Study NCT04051190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy group
Description: Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
Study NCT03053921 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: recession coverage
Description: recession coverage done using Zuchellis technique
Study NCT03053921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recession coverage and membrane
Description: recession coverage done using Zuchellis technique with placental membrane
Study NCT01703702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Study NCT01726387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Counseling
Description: Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
Study NCT01726387 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Depending on the conditions, patients get usual care of their general practitioner
Study NCT00814944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection of 440 micrograms sirolimus in each eye.
Study NCT00814944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection of 220 micrograms sirolimus in each eye.
Study NCT00814944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection of 880 micrograms sirolimus in each eye.
Study NCT00814944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus
Description: Subconjunctival injection of placebo in each eye.
Study NCT04519788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-301B
Description: Nasal Spray
Study NCT04519788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT-301A
Description: Nasal Spray
Study NCT01825356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation
Study NCT01825356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation
Study NCT03054064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Exoskeleton
Description: Six study sessions including five Indego training sessions over two weeks.
Study NCT01844505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01844505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01844505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Nivolumab
Study NCT01844505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Ipilimumab
Study NCT03260517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Coronary Drug-Coated Balloon Catheter
Description: Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
Study NCT01945801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasilactone
Description: Active drug (spironolactone 100 mg plus furosemide 20 mg).
Study NCT01945801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium-Restricted Diet
Description: The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
Study NCT01945801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
Study NCT02864927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular. 2 doses 3 months apart
Study NCT02864927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT03584464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
Study NCT01041976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI)
Description: Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
Study NCT01041976 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support and Education for Recovery (SER)
Description: Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
Study NCT03998163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mcg/kg
Description: IV CR845 0.5 mcg/kg administered three times/week
Study NCT04051190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass group
Description: Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)